ENTITY
Shijiazhuang Yiling Pharmaceutical

Shijiazhuang Yiling Pharmaceutical (002603 CH)

43
Analysis
Health CareChina
Shijiangzhuang Yiling Pharmaceutical Co Ltd develops, produces and sells Chinese patent medicine. The Company's major products include Tongxinluo capsules, Shensongyangxin capsules, Lotus Qingwen capsules, Qili Qiangxin capsules and Bazi Bushen capsules.
more
bearishHKEX
19 Nov 2023 05:30

Index Rebalance & ETF Flow Recap: FRTIB, Japan, CSI300, CSI500, STAR50, WuXi XDC, Asahi

This recap highlights Insights covering Asian index rebalances (announcements/ forecasts/ IPO Fast Entry/ M&A driven changes). We also highlight...

Logo
894 Views
Share
10 Feb 2025 06:40

China/HK: Passive Activity Expected Later This Month

There could be up to 10 adds/29 deletes for China in Feb. Flow varies from US$14m-175m and impact from 0.05x-22.75x ADV. Bestechnic Shanghai is a...

Logo
841 Views
Share
13 Dec 2024 06:23

CSI300/CSI500/CSI1000 Index Rebalance: US$9bn Round-Trip Trade

The CSI indices (and a bunch of others) rebalance at the close today - it's going to be a big volume day in China. The CSI300 adds have...

Logo
1.3k Views
Share
05 Nov 2024 05:30

CSI300 Index Rebalance Preview: Rising Markets and ETF Creations Take Round-Trip Trade to US$8.5bn

There could be 17 changes in Dec. Estimated 1-way turnover is 3%; 1-way trade is US$4.3bn. There are 14 stocks with over 2x ADV to trade. The adds...

Logo
926 Views
Share
15 Oct 2024 15:37

Quiddity Leaderboard CSI 300/​​500 Dec 24: Some Changes to Exp ADDs/DELs; Large Flow Expectations

We estimate for one-way flows of US$3.5bn and US$3.9bn for CSI 300 and CSI 500 respectively. The reference period for ADDs/DELs selection ends on...

Share
x